ADA 2026
Turning beta-cell death into a real-time endpoint.
American Diabetes Association · Scientific Sessions
InterceptIQ™ Platform · Clinical Stage
Detect disease
before symptoms begin.
Kihealth is pioneering a new category of molecular diagnostics that measures active disease biology — before traditional clinical markers become abnormal.
InterceptIQ™ · pipeline
KH-FLOW-01- 01Blood sampleSingle tube · routine draw
- 02Cell-free DNAIsolation · QC · low input
- 03Epigenetic analysisMethylation · fragmentomics
- 04AI intelligenceInterceptIQ™ v4.2 inference
- 05Actionable insightClinician-ready signal
SCROLL
Kihealth · Field Notes01 / 04
Liquid biopsy · Single tube
A single draw of blood holds the earliest signal of disease.
Plasma isolation · cell-free DNA extraction
625 Days Earlier Detection
87% Sensitivity
85% Specificity
12+ Patent Assets
ADA Innovation Award
CLIA Certified Laboratory
The problem
By the time disease declares itself, the damage is already done.
70–80%
Beta-cell mass lost before Type 1 Diabetes diagnosis.
30–60%
Children diagnosed in diabetic ketoacidosis.
Years
Required to reach conventional clinical endpoints.
Today
Current medicine measures the consequences of disease.
Kihealth
We measure disease itself.
The interception window
The window we've been missing.
Between the first molecular signs of beta-cell death and clinical symptoms lies a silent biological window — measurable, actionable, and previously invisible.
01
Autoimmune Attack
Pre-clinical biology
02
Beta Cell Death Begins
cfDNA released
KIHEALTH DETECTS
03
Compensation Falls
Insulin reserve drops
04
Glucose Rises
Metabolic threshold
05
Symptoms Appear
Clinical presentation
STANDARD DIAGNOSIS
Earlier signal
Up to 625 days earlier
Median lead-time observed in pediatric Stage-3 T1D cohorts vs. standard-of-care HbA1c diagnosis.
The InterceptIQ™ Platform
One platform. Multiple diseases.
A common molecular substrate — cell-free DNA, epigenetics, and AI — engineered to scale across every disease where active cellular injury leaves a signal in blood.
InterceptIQ™ platform architecture
A vertically integrated diagnostics stack.
Five tightly coupled layers — wet lab to clinical report — each instrumented, quality-controlled, and engineered for regulatory and payer review.
Samples processed (lifetime)38,400
Reads streaming (Gb/s)12.40
Inferences today1,283
Hover any layer to inspect
Pipeline
Programs across the disease spectrum.
Type 1 Diabetes
BetaIntercept™ T1
Real-time measurement of beta-cell death via cfDNA methylation.
EXPLORE
Type 2 Diabetes
BetaIntercept™ T2
Metabolic disease staging and progression monitoring.
EXPLORE
Alzheimer's & Neurodegeneration
NeuroIntercept™
Cortical neuron cfDNA for proteinopathy interception.
EXPLORE
Pancreatic Cancer
OncoIntercept™
Ductal-origin signal for early-stage screening.
EXPLORE
Scientific validation
Built for regulatory, payer, and pharmaceutical review.
Pre-registered acceptance criteria. Orthogonal confirmation. Prospective multi-center cohorts.
AUC
0.904
Stage-3 T1D classification
Sensitivity
87%
Pediatric prospective cohort
Specificity
85%
Auto-Ab+ vs. healthy controls
LoD
4.08
copies/µL at 95% probit
Detection Rate
73%
Stage-3 T1D cohort
Linearity (R²)PASS
0.9999
0.5 – 5,000 cp/µL
Limit of DetectionPASS
4.5cp/µL
95% probability · Probit
Diagnostic AUCPASS
0.979
T1D vs. control · n = 1,847
Inter-run CVPASS
3.2%
Across 28 days · 4 operators
SpecificityPASS
97.8%
At calibrated cutoff
SensitivityPASS
94.6%
At calibrated cutoff
How it works
From dying cell to clinical insight.
Six tightly-coupled steps. Each one engineered, validated, and operating under CLIA-regulated laboratory standards.
Sample → Signal → Intelligence
From a single tube of blood to clinical decision — in six instrumented stages.
The InterceptIQ pipeline is a continuous instrument loop. Every stage is quality-controlled, traceable, and engineered to preserve fragmentomic detail from picogram-level input through clinical reporting.
Fig. 03 / Sample-to-signal instrument looplive trace · stage 01 · T-0
Publications & research
Peer-reviewed, conference-presented, partner-validated.
Clinical Validation
Multi-locus insulin-gene methylation signal in pediatric Stage-3 T1D.
Diabetes · in revision
Yale Translational
Teplizumab response analysis via circulating beta-cell cfDNA.
Journal of Clinical Investigation
Partners & collaborators
Yale
Nemours
UF
Advarra
ADA
TEDDY
DAISY
Anschutz
Mayo
Broad Institute
Intellectual property
A defensible moat across every layer of the platform.
Composition of matter, methods, and machine-learned models — protected across the United States, Europe, and major Asian jurisdictions.
12+
Patent Assets
4
Issued & Acquired Assets
8+
Diagnostic Platform Patents
Future filings
NeurodegenerationOncologyMulti-OmicsAI / ML
Why Kihealth
Earlier signal. Better decisions. Better outcomes.
01
Earlier Detection
Measure disease before symptoms — when intervention is most effective.
02
Better Decisions
Understand the active biology driving disease, not just its downstream markers.
03
Better Outcomes
Intervene while disease remains reversible — and monitor response in real time.
Disease interception
The future of disease interception starts here.
Transforming disease biology into actionable intelligence — for clinicians, pharma partners, and the patients waiting on better answers.